The Center for Inquiry has requested in a letter to the head of the Food and Drug Administration requesting a reversal on its decision to green-light clinical trials of Dr. Stanislaw Burzynski.
The letter can be read here [PDF]. It states:
It is our understanding that the FDA has decided to allow the restoration of his status as a
researcher and the resumption of Investigational New Drug clinical trials overseen by an
Institutional Review Board (IRB) that is beholden to him. Given the behavior of Dr.
Burzynski and the Burzynski Research Institute (BRI) over the course of more than three
decades of failed research and trials, and in the face of a complete lack of scientific
evidence demonstrating the efficacy of their expensive and dangerous antineoplaston
treatment, we find the FDA’s decision perplexing and profoundly disturbing.
Burzynski’s cancer treatment clinic has been given the go-ahead to continue operation as we reported here: Burzynski to continue trials as FDA says ‘OK’ | Doubtful News.
40 years of nothing, a bias review board and a whole lot of money funneling to the clinic. FDA says, sure, go ahead.
This is truly a disappointing decision as it appears the FDA failed in their role for consumer protection. I guess the actually knowledgeable people have to step in and smack them across the head. Damn politics inferring…
Tip: Bob Blaskiewicz